Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China
Go back to Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China| INOVIO PHARMACEUTICALS, Inc. (NASDAQ: INO) | Delayed: 1.11 -0.01 (0.89%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.12 | 52 Week High | $11.69 | |||
| Open | $1.11 | 52 Week Low | $4.50 | |||
| Day High | $1.14 | P/E | N/A | |||
| Day Low | $1.10 | EPS | $-0.28 | |||
| Volume | 667,853 | |||||
